Global Markets Direct’s, ‘Neurotec Pharma SL - Product Pipeline Review - 2015’, provides an overview of the Neurotec Pharma SL’s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Neurotec Pharma SL’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- The report provides brief overview of Neurotec Pharma SL including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Neurotec Pharma SL’s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Neurotec Pharma SL’s pipeline products
Reasons to buy
- Evaluate Neurotec Pharma SL’s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Neurotec Pharma SL in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Neurotec Pharma SL’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Neurotec Pharma SL and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Neurotec Pharma SL - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Neurotec Pharma SL and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Our reports have been used by over 10K customers, including:
Summary University of Barcelona is an educational university that offers bachelor’s degrees, master’s degrees and research doctoral studies.The university provides EHEA bachelor’s degree courses, pre-EHEA degree, university master’s degree courses and doctoral programs. It offers courses in the areas of arts and...
Summary Laboratorios Farmaceuticos Rovi SA (Rovi) is a developer and manufacturer of prescription and hospital products.The company offers hospital products such as Iomeron and Iopamiro, Multihance, Y Prohance, Sonovue, contrast injection systems, Sodium Heparin and Siklos. Its diagnostic products comprise imaging...
Summary Spanish National Cancer Research Center (CNIO) is a medical research center that conducts cancer research programs.The center integrates basic and translational cancer research. It conducts various scientific programs, which include molecular oncology program, structural biology and biocomputing program,...
Summary Grupo Juste SAQF (Juste) is a developer and distributor of proprietary medicines and active pharmaceutical ingredients.The company offers oral and injectable radiological contrast media; diatrizoic acid, iothalamic acid, iohexol, iopamidol, iodixanol, MRI contrast agents, dihexazin, and others. Its services...